GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

TECH · Jun 30, 2024

BIO-TECHNE Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001558370-24-012430General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

27.52% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

5.42% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

25.80% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

15.51% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

66.41% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

17.83% · CORE · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

3.28% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20257/8 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 128.20%
Current: 27.52%
Delta: -100.68%

Capex Intensity Increased

Previous: 5.42%
Current: 5.42%
Delta: 0.01%

Cash Generation Decreased

Previous: 26.69%
Current: 25.80%
Delta: -0.90%

Inventory Pressure Decreased

Previous: 59.16%
Current: 15.51%
Delta: -43.65%

Margin Decreased

Previous: 67.43%
Current: 66.41%
Delta: -1.02%

Profitability Decreased

Previous: 22.08%
Current: 17.83%
Delta: -4.25%

Sbc Intensity Increased

Previous: 2.68%
Current: 3.28%
Delta: 0.60%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · TECH Fundamental State →Has State · BIO-TECHNE Corp →Transitioned To · TECH Fundamental State →Transitioned To · TECH BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · TECH CAPEX_INTENSITY_INCREASED →Transitioned To · TECH CASH_GENERATION_DECREASED →Transitioned To · TECH INVENTORY_PRESSURE_DECREASED →Transitioned To · TECH MARGIN_DECREASED →Transitioned To · TECH PROFITABILITY_DECREASED →Transitioned To · TECH SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.